News

Sun Pharmaceuticals Industries announced that the 34th Annual General Meeting(AGM) of the company will be held on 31 July 2026.

Sun Pharmaceuticals Industries announced that the Board of Directors of the Company at its meeting held on 22 May 2026, inter alia, have recommended the final dividend of Rs 5 per equity Share (i.e. 500%) , subject to the approval of the shareholders.

Net profit of Sun Pharmaceutical Industries rose 26.24% to Rs 2714.03 crore in the quarter ended March 2026 as against Rs 2149.88 crore during the previous quarter ended March 2025. Sales rose 13.61% to Rs 14559.75 crore in the quarter ended March 2026 as against Rs 12815.58 crore during the previous quarter ended March 2025.For the full year,net profit rose 5.04% to Rs 11479.42 crore in the year ended March 2026 as against Rs 10929.04 crore during the previous year ended March 2025. Sales rose 11.87% to Rs 58220.11 crore in the year ended March 2026 as against Rs 52041.25 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales14559.7512815.58 14 58220.1152041.25 12 OPM %27.1629.00 -30.4629.35 - PBDT4326.814279.82 1 19364.2117005.37 14 PBT3551.343616.03 -2 16426.3614429.98 14 NP2714.032149.88 26 11479.4210929.04 5 Powered by Capital Market - Live News

Sun Pharmaceuticals Industries will hold a meeting of the Board of Directors of the Company on 22 May 2026.

 Sun Pharmaceutical Industries (Sun Pharma) announced that CRISIL has reaffirmed the rating of the company`s long term bank facilities at CRISIL AAA and short term bank facilities and commercial paper at CRISIL A1+. CRISIL has placed the `Crisil AAA` rating on the long-term bank facilities on `Rating Watch with Developing Implications`. This rating action follows Sun Pharma`s announcement dated 27 April 2026, about signing a definitive agreement to acquire Organon & Co. (announcement). CRISIL has further communicated that it will remove the rating from watch and announce its final rating action post a comprehensive assessment of this acquisition.Further, ICRA has reaffirmed the rating on the long-term bank facilities for Sun Pharma, at ICRA AAA; Stable and short-term bank facilities and commercial paper at ICRA A1+ after taking note of the announcement.